305 related articles for article (PubMed ID: 22850513)
1. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir.
Pelosi LA; Voss S; Liu M; Gao M; Lemm JA
Antimicrob Agents Chemother; 2012 Oct; 56(10):5230-9. PubMed ID: 22850513
[TBL] [Abstract][Full Text] [Related]
2. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Friborg J; Levine S; Chen C; Sheaffer AK; Chaniewski S; Voss S; Lemm JA; McPhee F
Antimicrob Agents Chemother; 2013 Mar; 57(3):1312-22. PubMed ID: 23274666
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Activity of Combined NS5A Inhibitors.
O'Boyle DR; Nower PT; Gao M; Fridell R; Wang C; Hewawasam P; Lopez O; Tu Y; Meanwell NA; Belema M; Roberts SB; Cockett M; Sun JH
Antimicrob Agents Chemother; 2015 Dec; 60(3):1573-83. PubMed ID: 26711745
[TBL] [Abstract][Full Text] [Related]
4. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
[TBL] [Abstract][Full Text] [Related]
5. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Teraoka Y; Uchida T; Imamura M; Hiraga N; Osawa M; Kan H; Saito Y; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
J Gen Virol; 2018 Aug; 99(8):1058-1065. PubMed ID: 29916799
[TBL] [Abstract][Full Text] [Related]
6. Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.
Berger C; Romero-Brey I; Radujkovic D; Terreux R; Zayas M; Paul D; Harak C; Hoppe S; Gao M; Penin F; Lohmann V; Bartenschlager R
Gastroenterology; 2014 Nov; 147(5):1094-105.e25. PubMed ID: 25046163
[TBL] [Abstract][Full Text] [Related]
7. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
[TBL] [Abstract][Full Text] [Related]
8. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Kosaka K; Imamura M; Hayes CN; Abe H; Hiraga N; Yoshimi S; Murakami E; Kawaoka T; Tsuge M; Aikata H; Miki D; Ochi H; Matsui H; Kanai A; Inaba T; Chayama K
J Viral Hepat; 2015 Feb; 22(2):158-65. PubMed ID: 24943406
[TBL] [Abstract][Full Text] [Related]
9. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
[TBL] [Abstract][Full Text] [Related]
11. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Karino Y; Toyota J; Ikeda K; Suzuki F; Chayama K; Kawakami Y; Ishikawa H; Watanabe H; Hernandez D; Yu F; McPhee F; Kumada H
J Hepatol; 2013 Apr; 58(4):646-54. PubMed ID: 23178977
[TBL] [Abstract][Full Text] [Related]
12. HCV NS5A replication complex inhibitors.
Gao M; O'Boyle DR; Roberts S
Curr Opin Pharmacol; 2016 Oct; 30():151-157. PubMed ID: 27643675
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J
Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664
[TBL] [Abstract][Full Text] [Related]
14. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
16. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
[TBL] [Abstract][Full Text] [Related]
17. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
Hernandez D; Zhou N; Ueland J; Monikowski A; McPhee F
J Clin Virol; 2013 May; 57(1):13-8. PubMed ID: 23384816
[TBL] [Abstract][Full Text] [Related]
18. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
Wang C; Jia L; O'Boyle DR; Sun JH; Rigat K; Valera L; Nower P; Huang X; Kienzle B; Roberts S; Gao M; Fridell RA
Antimicrob Agents Chemother; 2014 Sep; 58(9):5155-63. PubMed ID: 24936600
[TBL] [Abstract][Full Text] [Related]
19. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice.
Lee SH; Moon JS; Pak BY; Kim GW; Lee W; Cho H; Kim S; Kim SJ; Oh JW
Sci Rep; 2018 Aug; 8(1):12469. PubMed ID: 30127498
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Wang C; Jia L; Huang H; Qiu D; Valera L; Huang X; Sun JH; Nower PT; O'Boyle DR; Gao M; Fridell RA
Antimicrob Agents Chemother; 2012 Mar; 56(3):1588-90. PubMed ID: 22203595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
